Summary
Vertex Pharmaceuticals Inc. reported a net loss attributable to Vertex of $170.1 million for the third quarter of 2014, compared to a net loss of $124.1 million in the same period of 2013. This widening loss was driven by a significant decrease in total revenues, down 19% to $179.0 million, primarily due to a sharp decline in INCIVEK product revenues (-88%) and a substantial drop in royalty revenues (-69%). These decreases were partially offset by increased KALYDECO net product revenues (+25%) and a surge in collaborative revenues, largely from an upfront payment related to an out-license agreement. Despite lower overall revenues, total operating costs and expenses decreased by 7% due to reduced R&D and SG&A spending, though restructuring expenses significantly increased (+239%). For the nine months ended September 30, 2014, the net loss widened to $561.9 million from $489.3 million in the prior year. Total revenues saw a substantial 49% decrease, primarily driven by the continued decline of INCIVEK sales. Operating costs and expenses also decreased significantly by 33%, largely due to the absence of a large intangible asset impairment charge recorded in the prior year and reduced R&D, SG&A, and cost of product revenues. The company ended the period with $1.48 billion in cash, cash equivalents, and marketable securities, providing a substantial liquidity buffer as it advances its key development programs, notably the combination of lumacaftor and ivacaftor for cystic fibrosis.
Financial Highlights
49 data points| Revenue | $178.99M |
| Cost of Revenue | $10.21M |
| Gross Profit | $168.78M |
| R&D Expenses | $190.94M |
| SG&A Expenses | $75.22M |
| Operating Expenses | $321.19M |
| Operating Income | -$142.20M |
| Net Income | -$170.06M |
| EPS (Basic) | $-0.72 |
| EPS (Diluted) | $-0.72 |
| Shares Outstanding (Basic) | 236.14M |
| Shares Outstanding (Diluted) | 236.14M |
Key Highlights
- 1Total revenues declined 19% year-over-year to $179.0 million in Q3 2014, primarily due to a steep drop in INCIVEK sales and reduced royalty revenues.
- 2KALYDECO net product revenues showed strong growth, increasing 25% in Q3 2014 to $126.8 million, driven by label expansions and a distribution model adjustment.
- 3Collaborative revenues surged by 317% to $33.5 million in Q3 2014, significantly boosted by a $30.0 million upfront payment from Janssen Inc. for an influenza drug candidate.
- 4Operating costs and expenses decreased by 7% in Q3 2014, driven by lower R&D and SG&A spending, but were impacted by a substantial increase in restructuring expenses (+239%).
- 5The company reported a net loss of $170.1 million for Q3 2014, a widening from $124.1 million in Q3 2013, reflecting the revenue decline and increased restructuring costs.
- 6Vertex submitted New Drug Applications (NDAs) for lumacaftor in combination with ivacaftor to the FDA and EMA in November 2014, a critical step for its most advanced cystic fibrosis program.
- 7Cash, cash equivalents, and marketable securities stood at $1.48 billion as of September 30, 2014, providing robust liquidity for ongoing operations and development activities.